Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

226 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Methodological innovations and stakeholder involvement in core outcome sets for skin diseases: a survey of the C3 working groups.
Ahmed A, Koza E, Shi V, Ma M, Haq M, Kottner J, Garg A, Ingram JR, Ezzedine K, Spuls PI, Beeckman D, Wolkenstein P, Fransen F, Noe MH, Langbroek GB, Bauer A, Thorlacius L, Horbach SER, Layton A, Apfelbacher C, Cahn BA, Pearlman R, Schlessinger DI, Alam M. Ahmed A, et al. Among authors: spuls pi. Arch Dermatol Res. 2024 Mar 18;316(4):109. doi: 10.1007/s00403-023-02812-1. Arch Dermatol Res. 2024. PMID: 38498269 No abstract available.
Clinical relevance and uptake of core outcome sets in dermatology.
Ahmed A, Koza E, Shi V, Ma M, Haq M, Kottner J, Garg A, Ingram JR, Ezzedine K, Spuls PI, Beeckman D, Wolkenstein P, Fransen F, Noe MH, Langbroek GB, Bauer A, Thorlacius L, Horbach SER, Layton A, Apfelbacher C, Cahn BA, Pearlman R, Schlessinger DI, Alam M. Ahmed A, et al. Among authors: spuls pi. Arch Dermatol Res. 2024 Jan 20;316(2):78. doi: 10.1007/s00403-023-02814-z. Arch Dermatol Res. 2024. PMID: 38244063 No abstract available.
Protocol of a scoping review of outcome domains in dermatology.
Nadir U, Ahmed A, Yi MD, Hisham FI, Dave L, Kottner J, Ezzedine K, Garg A, Ingram JR, Jemec GBE, Spuls PI, Kirkham JJ, Cahn B, Alam M. Nadir U, et al. Among authors: spuls pi. BMJ Open. 2024 Feb 6;14(2):e079632. doi: 10.1136/bmjopen-2023-079632. BMJ Open. 2024. PMID: 38320843 Free PMC article.
Implementation of the HOME core outcome set for clinical trials of atopic eczema-barriers and opportunities: the HOME IX meeting report.
Jacobson ME, Thomas KS, Apfelbacher CJ, Leshem YA, Williams HC, Gerbens LAA, Spuls PI, Schmitt J, Howells L, Katoh N, Simpson EL; Harmonising Outcome Measures for Eczema (HOME) Initiative. Jacobson ME, et al. Among authors: spuls pi. Arch Dermatol Res. 2023 Nov;315(9):2617-2622. doi: 10.1007/s00403-023-02647-w. Epub 2023 Jul 11. Arch Dermatol Res. 2023. PMID: 37432466
Measuring Signs of Atopic Dermatitis in Clinical Practice: A HOME-CP Consensus Statement.
Jacobson ME, Leshem YA, Apfelbacher C, Spuls PI, Gerbens LAA, Thomas KS, Williams HC, Katoh N, Howells L, Schmitt J, Deckert S, Seshadri R, Simpson EL; Harmonising Outcome Measures for Eczema (HOME) initiative. Jacobson ME, et al. Among authors: spuls pi. JAMA Dermatol. 2024 May 22. doi: 10.1001/jamadermatol.2024.1162. Online ahead of print. JAMA Dermatol. 2024. PMID: 38776110
Clinical and humoral responses after SARS-CoV-2 breakthrough infections in patients with immunosuppressants.
Stalman EW, Wieske L, Keijser JBD, van Dam KPJ, Kummer LYL, Wilbrink MF, van Kempen ZLE, Killestein J, Volkers AG, Tas SW, Boekel L, Wolbink GJ, van der Kooi AJ, Raaphorst J, Löwenberg M, Takkenberg RB, D'Haens GRAM, Spuls PI, Bekkenk MW, Musters AH, Post NF, Bosma AL, Hilhorst ML, Vegting Y, Bemelman FJ, Voskuyl AE, Broens B, Sanchez AP, van Els CACM, de Wit J, Rutgers A, de Leeuw K, Horváth B, Verschuuren JJGM, Ruiter AM, van Ouwerkerk L, van der Woude D, Allaart RCF, Teng YKO, van Paassen P, Busch MH, Brusse E, van Doorn PA, Baars AE, Hijnen D, Schreurs CRG, van der Pol WL, Goedee HS, Steenhuis M, Keijzer S, Cristianawati O, Brinke AT, Verstegen NJM, Zwinderman KAH, van Ham SM, Rispens T, Welkers MR, Jonges M, Eftimov F, Kuijpers TW; T2B! immunity against SARS-CoV-2 study group. Stalman EW, et al. Among authors: spuls pi. J Allergy Clin Immunol. 2024 May 17:S0091-6749(24)00503-7. doi: 10.1016/j.jaci.2024.04.031. Online ahead of print. J Allergy Clin Immunol. 2024. PMID: 38763170 Free article.
T cell activation markers CD38 and HLA-DR indicative of non-seroconversion in anti-CD20-treated patients with multiple sclerosis following SARS-CoV-2 mRNA vaccination.
Verstegen NJM, Hagen RR, Kreher C, Kuijper LH, Dijssel JVD, Ashhurst T, Kummer LYL, Palomares Cabeza V, Steenhuis M, Duurland MC, Jongh R, Schoot CEV, Konijn VAL, Mul E, Kedzierska K, van Dam KPJ, Stalman EW, Boekel L, Wolbink G, Tas SW, Killestein J, Rispens T, Wieske L, Kuijpers TW, Eftimov F, van Kempen ZLE, van Ham SM, Ten Brinke A, van de Sandt CE; T2B! immunity against SARS-CoV-2 study group. Verstegen NJM, et al. J Neurol Neurosurg Psychiatry. 2024 Mar 28:jnnp-2023-332224. doi: 10.1136/jnnp-2023-332224. Online ahead of print. J Neurol Neurosurg Psychiatry. 2024. PMID: 38548324 Free article.
226 results